Close Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $27K | Buy |
300
+200
| +200% | +$16.8K | ﹤0.01% | 190 |
|
|
2026
Q1 | $8K | Hold |
100
| – | – | ﹤0.01% | 232 |
|
|
2025
Q4 | $9K | Hold |
100
| – | – | ﹤0.01% | 230 |
|
|
2025
Q3 | $8K | Hold |
100
| – | – | ﹤0.01% | 231 |
|
|
2025
Q2 | $8K | Hold |
100
| – | – | ﹤0.01% | 222 |
|
|
2025
Q1 | $7K | Hold |
100
| – | – | ﹤0.01% | 221 |
|
|
2024
Q4 | $7K | Hold |
100
| – | – | ﹤0.01% | 219 |
|
|
2024
Q3 | $7K | Hold |
100
| – | – | ﹤0.01% | 229 |
|
|
2024
Q2 | $9K | Sell |
100
-1,722
| -95% | -$152K | ﹤0.01% | 222 |
|
|
2024
Q1 | $174K | Hold |
1,822
| – | – | 0.01% | 123 |
|
|
2023
Q4 | $139K | Hold |
1,822
| – | – | 0.01% | 129 |
|
|
2023
Q3 | $126K | Hold |
1,822
| – | – | 0.01% | 127 |
|
|
2023
Q2 | $172K | Hold |
1,822
| – | – | 0.01% | 115 |
|
|
2023
Q1 | $151K | Hold |
1,822
| – | – | 0.01% | 110 |
|
|
2022
Q4 | $136K | Hold |
1,822
| – | – | 0.01% | 100 |
|
|
2022
Q3 | $151K | Hold |
1,822
| – | – | 0.01% | 93 |
|
|
2022
Q2 | $173K | Hold |
1,822
| – | – | 0.01% | 98 |
|
|
2022
Q1 | $236K | Hold |
1,822
| – | – | 0.01% | 85 |
|
|
2021
Q4 | $236K | Hold |
1,822
| – | – | 0.01% | 85 |
|
|
2021
Q3 | $206K | Hold |
1,822
| – | – | 0.01% | 86 |
|
|
2021
Q2 | $189K | Hold |
1,822
| – | – | 0.01% | 97 |
|
|
2021
Q1 | $152K | Hold |
1,822
| – | – | 0.01% | 106 |
|
|
2020
Q4 | $166K | Hold |
1,822
| – | – | 0.01% | 80 |
|
|
2020
Q3 | $145K | Hold |
1,822
| – | – | 0.01% | 81 |
|
|
2020
Q2 | $126K | Sell |
1,822
-761
| -29% | -$54.1K | 0.01% | 88 |
|
|
2020
Q1 | $163K | Buy |
2,583
+2,283
| +761% | +$165K | 0.01% | 82 |
|
|
2019
Q4 | $23K | Hold |
300
| – | – | ﹤0.01% | 131 |
|
|
2019
Q3 | $22K | Hold |
300
| – | – | ﹤0.01% | 134 |
|
|
2019
Q2 | $19K | Hold |
300
| – | – | ﹤0.01% | 141 |
|
|
2019
Q1 | $19K | Sell |
300
-630
| -68% | -$36K | ﹤0.01% | 153 |
|
|
2018
Q4 | $76K | Buy |
930
+630
| +210% | +$31.9K | 0.01% | 106 |
|
|
2018
Q3 | $17K | Hold |
300
| – | – | ﹤0.01% | 161 |
|
|
2018
Q2 | $14K | Hold |
300
| – | – | ﹤0.01% | 159 |
|
|
2018
Q1 | $14K | Hold |
300
| – | – | ﹤0.01% | 165 |
|
|
2017
Q4 | $11K | Hold |
300
| – | – | ﹤0.01% | 177 |
|
|
2017
Q3 | $11K | Hold |
300
| – | – | ﹤0.01% | 169 |
|
|
2017
Q2 | $12K | Hold |
300
| – | – | ﹤0.01% | 170 |
|
|
2017
Q1 | $9K | Buy |
+300
| New | +$9.39K | ﹤0.01% | 177 |
|
Other funds holding EW
Close Asset Management's EW Position: Q2 2026 in Review
Close Asset Management increased its Edwards Lifesciences (EW) stake by 200% in Q2 2026, buying an estimated $16.8K and bringing the position to 300 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #190.
Close Asset Management first reported a position in EW in Q1 2017 and has held it in 38 quarters since. The position peaked at $236K in Q1 2022. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Close Asset Management held 300 shares of Edwards Lifesciences worth $27K as of Q2 2026.
- Close Asset Management bought 200 Edwards Lifesciences shares in Q2 2026, an estimated $16.8K.
- Edwards Lifesciences made up ﹤0.01% of Close Asset Management's portfolio in Q2 2026, its #190 holding.
- Close Asset Management first reported a position in Edwards Lifesciences in Q1 2017 and has held it in 38 quarters since.
- Close Asset Management's Edwards Lifesciences position peaked at $236K in Q1 2022.
- 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Close Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.